

NEYGLH, Central Laboratory Tests Not UKAS Accredited

Test/Service	Date submitted for addition to the UKAS Accreditation Schedule (if applicable)
FH (Familial Hypercholesterolaemia) NGS gene panel	N/A
WGS (Whole Genome Sequencing) - Any test facilitated by WGS pathways reported by our laboratory	N/A
NGS (Next Generation Sequencing) - Any test facilitated by oncology NGS pathways using Genexus reported by our laboratory Mutation detection in non small cell lung cancer	ETS submitted on 31/01/2024
NGS (Next Generation Sequencing) - Any test facilitated by oncology NGS pathways using TSO 500 reported by our laboratory. Tumour material: Mutation detection in gliomas, gists, endometrials, thyroids, melanomas and Kit mutations – mutations in EGFR, KRAS, NRAS and BRAF genes and detection of mutations in IDH1, IDH2, BRAF & TERT, H3F3A and HIST1H3B genes in brain tumours	ETS submitted on 31/01/2024
Detection of sex chromosomes using QF-PCR pathways Blood (EDTA anticoagulant), amniotic fluid, chorionic villus or solid tissue: Detection of sex chromosomes.	ETS submitted in Nov 2023
Fanconi Anaemia wet work	ETS submitted on 31/01/2024
Epic methylation array (wet work performed by Newcastle)	N/A
MSI+ (wet work performed by Newcastle and UKAS accredited)	ETS submitted Jan 2025, final approval pending
HRD analysis for ovarian cancer via TSO500 reagent (wet work Leeds, GLH distributed analysis reporting)	N/A
F8 inversions – screening and familial testing for Haemophilia A inversion mutations using Fragment analysis or diagnostic Gels.	ETS submitted 18/03/2025, awaiting UKAS assessment date